Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PKLR | P30613 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12003319 | 0.92 | ALDH1A1 (0.36) | ALDH1A1LMNASMN1; SMN2MAPK1PKLR | |
| SCHEMBL2849895 | 0.83 | PKM (0.53) | ALDH1A1LMNASMN1; SMN2MAPK1PKLR | |
| SCHEMBL2127502 | 0.82 | LMNA (0.36) | ALDH1A1LMNASMN1; SMN2MAPK1PKLR | |
| SCHEMBL2847102 | 0.79 | NPC1 (0.39) | ALDH1A1PKMRAB9ANAMPTCYP3A4 | |
| SCHEMBL2846508 | 0.79 | RAB9A (0.50) | ALDH1A1LMNASMN1; SMN2MAPK1PKLR | |
| SCHEMBL2847272 | 0.79 | ALDH1A1 (0.46) | ALDH1A1LMNASMN1; SMN2MAPK1PKM | |
| SCHEMBL2844715 | 0.77 | RAB9A (0.45) | ALDH1A1LMNASMN1; SMN2MAPK1PKM | |
| SCHEMBL1587553 | 0.76 | ALDH1A1 (0.32) | ALDH1A1LMNASMN1; SMN2MAPK1PKLR | |
| SCHEMBL16211169 | 0.76 | PKM (0.46) | ALDH1A1LMNASMN1; SMN2MAPK1PKLR | |
| SCHEMBL2842296 | 0.76 | RAB9A (0.44) | ALDH1A1LMNASMN1; SMN2MAPK1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2444120-B1 | Spirocyclic amiloride analogues as ENac blockers | NOVARTIS AG (CH) | 2017-09-27 | — | — | EP | disclosed |
| US-9643983-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2017-05-09 | — | — | US | disclosed |
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| US-9139586-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2015-09-22 | — | — | US | disclosed |
| US-20140171421-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-8697687-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20130012500-A1 | ORGANIC COMPOUNDS | BHALAY GURDIP (GB) | 2013-01-10 | — | — | US | disclosed |
| EP-2520574-A1 | Amiloride analogues substituted on the cyclic guanidine moiety as ENaC blockers for treating respiratory diseases | Novartis AG (CH) | 2012-11-07 | — | — | EP | disclosed |
| EP-2231280-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-20100130506-A1 | Organic Compounds | NOVARTIS AG | 2010-05-27 | — | — | US | disclosed |
| WO-2009074575-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012500-A1 | ORGANIC COMPOUNDS | OR10J3, REN, CACNA1E | ALDH1A1 1317/4885LMNA 2001/4885SMN1; SMN2 1712/4885 |
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | SCNN1B, SCNN1A, SCNN1G | ALDH1A1 2199/4885LMNA 1078/4885SMN1; SMN2 812/4885 |
| US-20100130506-A1 | Organic Compounds | OR10J3, REN, CACNA1E | ALDH1A1 1317/4885LMNA 2001/4885SMN1; SMN2 1712/4885 |
| US-20140171421-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | SCNN1B, SCNN1A, SCNN1G | ALDH1A1 2199/4885LMNA 1078/4885SMN1; SMN2 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.